Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus neoadjuvant radiotherapy for high-risk localized extremity soft tissue sarcoma
2018-001360-39Phase 2Active
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in soft tissue sarcoma (STS), Liposarcoma and Malignant Fibrous Histiocytoma (MFH) (2 arms), sponsored by Sarcoma Alliance for Research through Collaboration. Primary endpoint: Disease-free survival. Started Jun 2021; status: active.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)LiposarcomaMalignant Fibrous Histiocytoma (MFH)
Beyond the preview
Go deeper on 2018-001360-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001360-39.